Ectopic Pregnancy

Ectopic pregnancy is a pregnancy that implants outside the endometrial cavity of the uterus. The fallopian tube is by far the most common site, accounting for more than 90% of cases — most often the ampullary segment — with the abdomen, cervix, ovary, and a prior cesarean scar together making up the small remaining minority.^[1] Ectopic pregnancy is estimated to complicate roughly 2% of all reported pregnancies, though the true current incidence is difficult to pin down precisely in either Canada or the United States, since so many cases are diagnosed and managed entirely in an outpatient setting, outside the reach of national surveillance systems; among patients presenting to an emergency department with first-trimester bleeding, pain, or both, the prevalence of ectopic pregnancy has been reported as high as 18%.^[1]

Despite genuine advances in early diagnosis and management, ruptured ectopic pregnancy remains a leading — and largely preventable — cause of pregnancy-related death: it accounted for 2.7% of all pregnancy-related deaths and was the leading cause of hemorrhage-related maternal mortality in recent United States surveillance data.^[1] That single fact should anchor how this chapter is used. For a community or prenatal pharmacist, ectopic pregnancy is fundamentally a recognize-and-refer-promptly condition. Once a patient is safely under specialist obstetric or emergency care, methotrexate becomes the central pharmacotherapy for carefully selected, hemodynamically stable, unruptured cases — and pharmacists have a genuine, ongoing counselling and monitoring-support role during that phase, covered in detail in Choose Initial Treatment and Pharmacologic Treatment Options.

Where implantation occurs

Ectopic implantation occurs in the fallopian tube in more than 90% of cases, most often the ampullary segment. Nontubal sites are collectively uncommon — the abdomen (about 1%), cervix (about 1%), ovary (1-3%), and a prior cesarean scar (1-3%) — but nontubal ectopic pregnancies generally need individualized, specialist-directed management rather than the standard tubal methotrexate protocols this chapter focuses on.^[1]

A genuinely variable presentation

The classic teaching triad — abdominal pain, vaginal bleeding, and amenorrhea in early pregnancy — is a reasonable starting point, but ectopic pregnancy is a genuine diagnostic pitfall precisely because presentation is so inconsistent: it ranges from no symptoms at all to catastrophic hemorrhagic shock, and roughly half of all patients ultimately diagnosed with an ectopic pregnancy have no identifiable risk factor.^[1] Every sexually active, reproductive-aged patient who presents with abdominal pain or vaginal bleeding should be screened for pregnancy regardless of current contraceptive use or reported last menstrual period, and any patient with known risk factors who becomes pregnant should be evaluated for possible ectopic pregnancy even in the complete absence of symptoms.^[1]

Signs suggesting rupture

Hemodynamic instability, an acute abdomen, and classic referred shoulder-tip pain from diaphragmatic irritation by intraperitoneal blood are findings that demand emergency evaluation, not routine outpatient follow-up (see Red Flags & Refer). Early diagnosis, aided by a genuinely high index of suspicion in any at-risk patient, is what actually prevents progression to this point.^[1]

Heterotopic pregnancy

A concurrent intrauterine and ectopic pregnancy — heterotopic pregnancy — is rare after natural conception, estimated at 1 in 4,000 to 1 in 30,000 pregnancies, but is dramatically more common after assisted reproduction, with estimates as high as 1 in 100 pregnancies conceived through in vitro fertilization.^[1] A confirmed intrauterine pregnancy does not fully exclude a coexisting ectopic pregnancy in a patient who conceived through IVF — this distinction matters directly for methotrexate eligibility (see Choose Initial Treatment and Special Populations).

Roughly half of all patients diagnosed with ectopic pregnancy have no identifiable risk factor — risk-factor screening is a useful adjunct, never a substitute for a low threshold to test and image any patient with a compatible presentation.^[1]

• A previous ectopic pregnancy — the single strongest predictor. Recurrence risk after one prior ectopic pregnancy is approximately 10% (odds ratio 3.0, 95% CI 2.1-4.4); after two or more prior ectopic pregnancies, recurrence risk rises to over 25% (odds ratio 11.17, 95% CI 4.0-29.5).
• Previous damage to the fallopian tubes, from any cause.
• A history of ascending pelvic infection (pelvic inflammatory disease).
• Previous pelvic or fallopian tube surgery, including tubal sterilization.
• A history of infertility itself, independent of how the current pregnancy was conceived.
• Conception through assisted reproductive technology — tubal factor infertility specifically, and transfer of multiple embryos, are both independently associated with a higher risk.
• A history of cigarette smoking, and maternal age over 35 years — real but comparatively less significant risk factors.
• An intrauterine device (IUD) in place at the time of conception. This needs careful framing for patient counselling: IUDs make pregnancy far less likely overall than using no contraception at all, so they do not raise a patient's absolute risk of ectopic pregnancy in the way this point is sometimes misunderstood. However, on the rare occasion that a pregnancy does occur with an IUD in place, that pregnancy is disproportionately likely to be ectopic — up to 53% of pregnancies occurring with an IUD in situ are ectopic. A patient who becomes pregnant with an IUD in place should always be evaluated for ectopic pregnancy.

Not associated with an increased risk of ectopic pregnancy: oral contraceptive use, emergency contraception failure, a previous elective termination of pregnancy, a previous pregnancy loss, or a previous cesarean delivery.^[1]

Minimum diagnostic evaluation

The minimum diagnostic evaluation of a suspected ectopic pregnancy is a transvaginal ultrasound combined with confirmation of pregnancy; serial transvaginal ultrasonography, serial quantitative serum hCG measurement, or both are often needed to reach a confident diagnosis.^[1] A single hCG value, on its own, cannot establish either the viability or the location of a pregnancy — diagnosis rests on the combination of ultrasound findings, the trend across at least two hCG measurements, and the overall clinical picture.^[1]

Transvaginal ultrasound

Ultrasound definitively diagnoses an ectopic pregnancy when a gestational sac containing a yolk sac, an embryo, or both is identified outside the uterine cavity — most often as an adnexal mass separate from the ovary, sometimes with an associated hypoechoic area. Most ectopic pregnancies, however, never progress to this clearly diagnostic stage, and an adnexal mass on its own has only about 80% positive predictive value, since it can be confused with a paratubal cyst, hydrosalpinx, corpus luteum, endometrioma, or bowel.^[1] A visualized intrauterine gestational sac with a yolk sac is expected between 5 and 6 weeks' gestation regardless of whether the pregnancy is a singleton or a multiple gestation; accurate gestational-age calculation — not an absolute hCG value — is the best determinant of when a normal pregnancy should become visible on transvaginal ultrasound.^[1]

The hCG discriminatory zone

When gestational age is uncertain, hCG is used as a surrogate to help interpret a nondiagnostic ultrasound. The "discriminatory zone" is the hCG value above which the landmarks of a normal intrauterine pregnancy should be visible on ultrasound; the absence of an intrauterine gestational sac at an hCG level above this threshold strongly suggests a nonviable gestation — either an early intrauterine pregnancy loss or an ectopic pregnancy — with roughly 50-70% of such findings ultimately proving to be ectopic.^[1] ACOG cautions that if a discriminatory-zone value is used at all, it should be set conservatively high — as high as 3,500 mIU/mL — specifically to avoid misdiagnosing, and potentially interrupting, an early wanted intrauterine pregnancy; a patient carrying a multiple gestation can have hCG levels above traditional discriminatory thresholds before ultrasound findings catch up.^[1] The Society of Obstetricians and Gynaecologists of Canada frames its own discriminatory zone somewhat lower, in the 1,500-2,500 IU/L range, as part of a broader framework that risk-stratifies a pregnancy of unknown location as high or low risk for ectopic pregnancy — a useful reminder that this threshold is a probabilistic aid to interpretation, not a rigid cutoff, and that an isolated hCG value should never override a patient's overall clinical stability and the full ultrasound picture.^[2]

Serial hCG trends

In a normal early pregnancy, serum hCG rises in a curvilinear fashion until it plateaus at around 100,000 mIU/mL by about 10 weeks' gestation.^[1] The old teaching that hCG should simply "double every 48 hours" is outdated and too strict — the expected minimum rate of rise is actually slower, and depends on the initial hCG value itself. A landmark analysis of hCG curves in confirmed normal intrauterine pregnancies found an expected minimum 48-hour rise of about 49% for an initial hCG under 1,500 mIU/mL, 40% for an initial value of 1,500-3,000 mIU/mL, and 33% for an initial value over 3,000 mIU/mL.^[3] A rise slower than this minimum threshold in 48 hours is suspicious for an abnormal pregnancy — either ectopic or an early intrauterine loss — because 99% of normal intrauterine pregnancies rise faster than this minimum. Even so, an hCG pattern fully consistent with a growing or resolving pregnancy does not itself eliminate the possibility of an ectopic pregnancy, and a declining hCG trend should never be treated as diagnostic on its own — a patient with a possible ectopic pregnancy and a falling hCG still needs monitoring through to a nonpregnant level, because rupture can occur even while hCG values are decreasing or already low.^[1]

Pregnancy of unknown location

A pregnant patient with no definitive intrauterine or ectopic finding on ultrasound has a "pregnancy of unknown location" — a transient working state, not a diagnosis in itself, and every reasonable effort should be made to reach a definitive diagnosis rather than treat empirically on the basis of an unresolved picture.^[1] A clinically stable patient with a pregnancy of unknown location who wishes to continue the pregnancy, if it is intrauterine, should have a repeat transvaginal ultrasound, serial hCG measurement, or both, to confirm the diagnosis and guide management — confirming the diagnosis before any treatment, particularly before methotrexate, is essential to avoid the genuine risk of interrupting or harming an ongoing wanted intrauterine pregnancy through misdiagnosis.^[1] The SOGC guideline frames this as risk-stratifying a pregnancy of unknown location into a high- or low-risk category, and suggests that expectant management with continued monitoring is reasonable for a patient at low risk — specifically, an initial hCG under 1,000 IU/L that is already falling by at least 15-20% over 48 hours, with no significant adnexal hematoma on ultrasound.^[2]

Where a progressing intrauterine pregnancy has been reasonably excluded, uterine aspiration can help distinguish an early intrauterine pregnancy loss from an ectopic pregnancy by identifying the presence or absence of chorionic villi in the aspirate — the timing and choice of this step should be made through shared decision-making that weighs maternal risk against the possibility of interrupting a pregnancy that is actually progressing normally.^[1] If villi are identified, a failed intrauterine pregnancy is confirmed and no further evaluation is needed. If villi are not confirmed, hCG should be monitored starting 12-24 hours after aspiration: a decrease of 50% or more in that window is more consistent with a failed intrauterine pregnancy than with ectopic pregnancy and can reasonably be followed with serial hCG alone, while a plateau, an increase, or a smaller decline needs closer follow-up and a materially higher index of suspicion for ectopic pregnancy.^[1]

Investigations

• Transvaginal ultrasound.
• Serial quantitative serum hCG, at least 2 days apart when the diagnosis is not yet clear.
• Complete blood count, including hemoglobin/hematocrit — a baseline for any patient with bleeding or suspected rupture, and before methotrexate.
• Blood type and Rh(D) status, if not already known — needed to guide Rh(D) immune globulin decisions (see Special Populations) and before any surgical management.
• Serum creatinine and liver transaminases (AST/ALT) — required before methotrexate, since clinically important renal or hepatic dysfunction is an absolute contraindication (see Choose Initial Treatment).

• Recognize possible ectopic pregnancy early and confirm the diagnosis accurately — avoiding both a missed or delayed diagnosis that allows progression to rupture, and a false-positive diagnosis that risks interrupting a normal, wanted intrauterine pregnancy.
• Prevent, and if it occurs promptly treat, tubal rupture and hemorrhagic shock — the single highest-stakes goal in this condition.
• Select the right management strategy — expectant, medical (methotrexate), or surgical — based on hemodynamic stability, eligibility criteria, and the patient's own preferences and fertility goals.
• For patients treated with methotrexate, monitor closely enough to detect treatment failure early and escalate to surgical management before rupture occurs, not after.
• Prevent Rh(D) alloimmunization in Rh-negative patients using current, gestational-age-tailored dosing guidance rather than outdated blanket practice.
• Counsel every patient clearly on rupture warning signs, the specific precautions required during methotrexate treatment, and the implications for future pregnancy — recurrence risk, required contraception, and methotrexate's teratogenic window.

• Repeat rupture-warning-sign education at every visit for any patient being managed expectantly or medically as an outpatient (see Red Flags & Refer) — this is not a one-time conversation at diagnosis.
• Acknowledge the loss explicitly. Regardless of how it is managed, an ectopic pregnancy is a pregnancy loss, and patients benefit from that being named rather than the conversation staying purely procedural; offer or point toward support resources where locally available.
• During methotrexate treatment, advise avoiding vigorous physical activity and sexual intercourse until resolution is confirmed, given the theoretical risk of provoking tubal rupture, and limiting pelvic examinations and unnecessary ultrasounds where clinically reasonable.^[1]
• Hemodynamically stable single-dose and two-dose methotrexate treatment is managed entirely as an outpatient — bed rest or hospitalization is not routinely required simply because a diagnosis of ectopic pregnancy has been made.
• Emphasize that attending every scheduled hCG follow-up visit is itself part of treatment, not an optional check-in — resolution is confirmed by laboratory trend, not by how a patient feels.
• For patients managed surgically, defer specific post-operative wound and activity guidance to the surgical team, but reinforce the same rupture/complication warning signs during the immediate recovery period and the need for continued hCG monitoring after salpingostomy specifically (see Monitoring & Follow-Up).

Rh(D)-negative patients

Current Canadian guidance on this point has genuinely changed and is worth flagging explicitly, since older teaching defaulted to giving Rh(D) immune globulin for every Rh-negative patient with any pregnancy loss or ectopic pregnancy. The 2024 SOGC guideline on Rh D alloimmunization now recommends, for non-sensitized Rh D-negative patients with a threatened, spontaneous, or induced abortion, ectopic pregnancy, or molar pregnancy:^[5]

• Before 8 weeks' gestation: do not administer Rh(D) immune globulin (conditional recommendation, low-certainty evidence).
• 8-12 weeks' gestation: suggest not administering Rh(D) immune globulin; a more risk-averse patient may reasonably still be offered it (conditional recommendation, low-certainty evidence).
• After 12 weeks' gestation: administer 300 mcg of Rh(D) immune globulin (conditional recommendation, low-certainty evidence) — unless the diagnosis is a confirmed complete molar pregnancy, in which case it is not required.

Because most ectopic pregnancies are diagnosed well before 12 weeks' gestation, this means Rh(D) immune globulin is not routinely indicated for the great majority of ectopic pregnancy presentations under current Canadian guidance — confirm gestational age and local protocol explicitly rather than administering it reflexively.^[5]

Breastfeeding

Breastfeeding is an absolute contraindication to methotrexate — the drug is excreted in breast milk and is directly toxic to rapidly dividing tissue. Methotrexate should not be given to a breastfeeding patient; surgical management is the appropriate alternative if medical eligibility criteria would otherwise be met.^[1]

Renal and hepatic impairment

Methotrexate is cleared primarily by the kidneys and is directly toxic to hepatocytes, so clinically important renal or hepatic dysfunction is an absolute contraindication to its use — confirm creatinine and liver transaminases before treatment (see Assessment & Diagnosis).^[1]

Desired concomitant (heterotopic) pregnancy

Systemic methotrexate should not be offered when there is a desired concomitant intrauterine pregnancy — a genuine, deliberate exception to the usual eligibility framework, reflecting methotrexate's direct fetotoxicity to any coexisting pregnancy the patient wishes to continue.^[2] Local (intra-gestational-sac) treatment or surgical management of the ectopic component is used instead in this situation, under specialist direction.

Future fertility and pregnancy timing

Available evidence, while limited, suggests methotrexate treatment for ectopic pregnancy does not adversely affect subsequent fertility or ovarian reserve — a prospective study found no difference in anti-Müllerian hormone levels or reproductive outcomes, and no significant difference in oocyte yield among patients undergoing fertility treatment before versus after methotrexate exposure.^[1] Product labelling recommends avoiding pregnancy during treatment and for at least one ovulatory cycle afterward, reflecting the roughly 4-12 weeks methotrexate takes to fully clear the serum. However, methotrexate has been detected in liver tissue up to 116 days after a dose, and while limited evidence has not shown an increased rate of congenital anomalies or early pregnancy loss in patients who conceive shortly after treatment, some experts continue to recommend a more conservative delay of at least 3 months after the last dose before attempting a subsequent pregnancy.^[1] Counsel patients toward the more conservative window and confirm reliable contraception is in place for that period, while deferring to their own obstetric provider's specific direction.

A patient with a prior ectopic pregnancy carries roughly a 10% recurrence risk in a future pregnancy after one prior episode, rising to over 25% after two or more (see Risk Factors) — a history of ectopic pregnancy is a reason for a very early ultrasound in any future pregnancy, specifically to confirm intrauterine location.

During methotrexate treatment

Check hCG on Day 4 and Day 7 after the first dose. A decline of at least 15% between those two values is reassuring; anything less meets the defined treatment-failure threshold and needs action (see Treatment Failure / Next Step).^[1] Once an adequate decline is confirmed, continue weekly hCG measurement until a nonpregnant level is reached, which is usually complete in 2-4 weeks but can take up to 8 weeks.^[1] Some abdominal pain 2-3 days after the injection is an expected effect of methotrexate on trophoblastic tissue and, in the absence of signs of overt rupture, can generally be managed by monitoring hemoglobin and intraperitoneal fluid on ultrasound rather than assuming failure or rupture outright — but any new severe pain, dizziness, fainting, or heavy bleeding still needs the same emergency evaluation as any other suspected rupture (see Red Flags & Refer).^[1] Watch for gastrointestinal adverse effects (the most common), a transient rise in liver transaminases that typically resolves after treatment ends, and — rarely — alopecia or pneumonitis; counsel patients to report fever or respiratory symptoms promptly.^[1]

After surgical management

After salpingostomy specifically, monitor hCG serially to confirm resolution of trophoblastic tissue and detect a persistent ectopic pregnancy early — this surveillance is not needed after a complete salpingectomy, since the entire affected segment has been removed.^[1]

Long-term and future pregnancy

Discuss future-pregnancy recurrence risk at the postpartum or post-treatment follow-up visit (see Special Populations), and confirm the patient understands that a very early ultrasound is warranted in any subsequent pregnancy. Where the loss has been emotionally significant, confirm the patient has a route back to support — this does not need to end with the final hCG result.

1. hCG decreases by less than 15% between Day 4 and Day 7 after a single-dose or two-dose methotrexate treatment: re-administer methotrexate 50 mg/m² IM and recheck hCG per protocol — this pattern is the defined signal of a high risk of treatment failure and needs action, not simply a longer wait.
2. hCG fails to decrease after two total methotrexate doses: consider surgical management rather than a third dose.
3. hCG plateaus or rises again during follow-up after an initially adequate decline: consider retreatment with methotrexate for a persistent ectopic pregnancy.
4. Treatment failure in a patient who did not have a pretreatment uterine aspiration: this should raise concern for an unrecognized abnormal intrauterine pregnancy rather than simple ectopic treatment failure — consider uterine aspiration before repeating methotrexate or proceeding to surgery, unless there is already clear evidence of a tubal ectopic pregnancy.
5. New severe pain, dizziness, fainting, or heavy vaginal bleeding at any point during medical management: treat as suspected rupture and refer for immediate emergency evaluation — do not attribute new severe symptoms to the expected post-injection abdominal discomfort without assessment (see Red Flags & Refer).
6. Persistent trophoblastic tissue suspected after salpingostomy (hCG plateau or rise on post-operative surveillance): continue close hCG monitoring; a single prophylactic methotrexate dose or repeat surgery may be needed.
7. Expectant management fails (intractable or significantly increasing pain, an inadequate hCG decline, or tubal rupture with hemoperitoneum): move to medical or surgical management as clinically appropriate rather than continuing to observe.

• Assuming a patient is "too low-risk" to need pregnancy testing or ectopic pregnancy consideration — roughly half of all patients diagnosed with ectopic pregnancy have no identifiable risk factor.
• Reassuring a patient with an IUD in place that pregnancy, and therefore ectopic pregnancy, is not possible — IUDs make pregnancy overall far less likely, but a pregnancy that does occur with an IUD in place is disproportionately likely to be ectopic.
• Treating a single hCG value, in isolation, as diagnostic of viability or location — diagnosis requires the trend across serial values plus ultrasound correlation, never one number alone.
• Applying the outdated "hCG must double every 48 hours" rule rigidly — the actual expected minimum rise is slower and depends on the initial hCG value.
• Assuming a declining hCG trend rules out ongoing risk — rupture can occur while hCG values are falling or already low; a patient with a possible ectopic pregnancy needs monitoring through to a confirmed nonpregnant level, not just a reassuring downward trend.
• Giving methotrexate before reasonably excluding an intrauterine pregnancy the patient wishes to continue, or before confirming no absolute contraindication is present.
• Missing the treatment-failure signal — failure of hCG to fall by at least 15% from Day 4 to Day 7 needs action (retreatment or surgery), not simply a longer wait for the next scheduled visit.
• Letting a patient continue folic-acid-containing supplements or NSAIDs during methotrexate treatment — both can reduce its efficacy.
• Reflexively giving Rh(D) immune globulin to every Rh-negative patient with an ectopic pregnancy — current Canadian guidance recommends against routine administration before 12 weeks' gestation, which covers most ectopic pregnancy presentations (see Special Populations).
• Attributing new severe abdominal pain, dizziness, or bleeding during methotrexate treatment entirely to the drug's expected post-injection effect without assessing for true rupture.
• Treating expectant management as a default "wait and see" approach for an uncertain diagnosis, rather than a deliberate option reserved for a fully counselled, asymptomatic patient with objective evidence of resolution.

How to use this table: doses are adult obstetric/gynecologic doses for ectopic pregnancy specifically and require patient-specific confirmation (renal/hepatic function, body surface area). Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

First-Line Medical Management — Methotrexate

Considered for a hemodynamically stable patient with an unruptured mass and no absolute contraindication (see the contraindications table below).^[1][2]

Rescue Therapy — Fixed Multiple-Dose Protocol Only

Not needed for the more commonly used single-dose or two-dose regimens.^[1]

Rh(D) Alloimmunization Prevention — Gestational-Age-Dependent

Current (2024) Canadian guidance changed this from older blanket practice — most ectopic pregnancies are diagnosed before 12 weeks, when routine administration is now recommended against.^[5]

Absolute contraindications to methotrexate — do not treat medically

Evidence note: drug inventory, dosing, adverse effects, and comments reflect current SOGC guidance, cross-checked against ACOG's more granular protocol and contraindications detail, and the primary hCG-kinetics and single-dose-versus-multidose evidence each is based on.^[2][5][1][3]